A phase II study of aprepitant, palonosetron, dexamethasone and olanzapine for the prevention of cisplatin-based hemotherapy-induced nausea and vomiting for thoracic malignancy - A phase II study of aprepitant, palonosetron, dexamethasone and olanzapine for the prevention of cisplatin-based hemotherapy-induced nausea and vomiting for thoracic malignancy

Shizuoka cancer center0 sites30 target enrollmentStarted: May 10, 2015Last updated: October 17, 2023

Conditions

Trial Snapshot

No summary available.

•1) Prior severe hypersensitivity to aprepitant, 5HT3 receptor antagonist, corticosteroids or olanzapine 2) Patients who do not have enough whole body state to the antineoplastic agents treatment 3) Severe complication 4) Patients who have conceived child or desire childbearing or breast-feed their baby 5) Patients enforced radiotherapy at the bottom of diaphragm on the period between 6 days before and 6 days after of the date of first therapy 6) Patients who cannot stay in hospital till the 6th day of chemotherapy 7) HbA1c (NGSP) >= 6.5. FBS >= 126mg/dl or BS >= 200mg/dl 8) Diabetes mellitus 9) Patient with nausea and vomiting needing for medical treatment beore chemotherapy 10) Patient who have previous history or familial history of malignant syndrome 11) CK more than 2.5 times of institutional upper normal limit 12) Patients with active infection 13) Patient who cannot stop smoking during this study 14) BMI (body mass index) >= 35 15) Patients who take a medicine regularly ,for example , 5HT3 receptor antagonists, corticosteroids, antidopamine agonists, phenothiazine tranquilizers,antihistamine drugs, benzodiazepine,agents, etc

Sponsor